Welcome to our dedicated page for ONXEO news (Ticker: ONXEO), a resource for investors and traders seeking the latest updates and insights on ONXEO stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ONXEO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ONXEO's position in the market.
Onxeo S.A. has appointed Bryan Giraudo, COO & CFO of Gossamer Bio, as an independent member of its Board of Directors, replacing Thomas Hofstaetter. Giraudo brings extensive financial expertise and a strong network in the U.S. life sciences sector. His appointment aims to strengthen Onxeo's international focus, especially in developing its innovative oncology drug, AsiDNA™, which targets DNA Damage Response (DDR). Chairwoman Shefali Agarwal and CEO Judith Greciet lauded his financial acumen and strategic insights.
Onxeo S.A. has announced the appointment of Dr. Robert L. Coleman and Dr. Jacques Mallet as independent members of its Board of Directors. Dr. Coleman, Chief Scientific Officer of US Oncology Network, brings extensive oncology expertise, particularly in ovarian cancer research. Dr. Mallet, former SVP at Sanofi, offers over 30 years of experience in pharmaceutical R&D and corporate strategy. This strategic appointment aims to enhance Onxeo's clinical development, particularly for its innovative oncology drug AsiDNA™. The company's focus is on pioneering treatments targeting DNA Damage Response in oncology.
Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North: ONXEO) has appointed
Onxeo S.A., a clinical-stage biotechnology company, announced the appointment of Dr. Shefali Agarwal as the new Chairwoman of the Board of Directors on July 29, 2021. She succeeds Danièle Guyot-Caparros, who will continue as an independent board member and Audit Committee Chair. Dr. Agarwal brings extensive experience from her role as Chief Medical and Development Officer at Epizyme, Inc. Her expertise is expected to support Onxeo's ambitious clinical programs and growth, particularly in the U.S. market.